Mateon Therapeutics, Inc. (OTCMKTS:MATN – Get Free Report) shares crossed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $0.04 and traded as high as $0.06. Mateon Therapeutics shares last traded at $0.05, with a volume of 179,981 shares traded.
Mateon Therapeutics Price Performance
The firm has a 50 day moving average of $0.05 and a 200-day moving average of $0.04.
About Mateon Therapeutics
Mateon Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-beta, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus.
Featured Stories
- Five stocks we like better than Mateon Therapeutics
- How to Read Stock Charts for Beginners
- 3 Mid-Cap to Mega-Cap Stocks Have Announced Significant Buybacks
- Quiet Period Expirations Explained
- These 3 Stocks Have Huge Last 12 Months Shareholder Yields
- What Are Treasury Bonds?
- Prominent Hedge Fund Acquires Huge Stake in HPE: Is It a Buy Now?
Receive News & Ratings for Mateon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mateon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
